Literature DB >> 1656861

Absorption, disposition, and urinary metabolism of 14C-rifabutin in rats.

R Battaglia1, G Salgarollo, G Zini, L Montesanti, M Strolin Benedetti.   

Abstract

14C-rifabutin was given orally (25 mg/kg) and intravenously (i.v.) (10 mg/kg) to female Sprague-Dawley rats. Radioactivity was eliminated by both the renal and fecal routes, amounting to 44.49 and 43.39% of the dose, respectively, in urine and feces at 96 h after the oral dose and to 47.81 and 40.76% of the dose, respectively, in urine and feces after the i.v. dose. Differences between the two routes of administration were negligible. Tissue distribution of radioactivity after the oral dose was investigated by the combustion technique. At 2 h, the highest concentration of radioactivity was observed in the liver, followed by the lung, abdominal adipose tissue, and spleen, whereas at 72 h, the sequence was abdominal adipose tissue, liver, spleen, bone marrow, and lung. Brain levels of radioactivity were very low. The results of whole-body autoradiography after i.v. administration confirmed the above. Whole-body autoradiography of pregnant rats showed higher concentrations of radioactivity in the uterus than in the placenta and trace levels in the fetuses up to 8 h. Radioactivity was absent in the amniotic fluid. The urinary metabolism was studied by radio-high-pressure liquid chromatography. Rifabutin accounted for 7.4 and 7.2% of the dose in 0- to 48-h urine after oral and i.v. administration, respectively. Metabolites 31-OH rifabutin and 25-O-deacetyl rifabutin amounted to 4.3 and 1.6% of the dose, respectively, after oral administration and to 2.6 and 0.7% of the dose, respectively, after i.v. administration. The remaining urinary radioactivity was mainly due to polar compounds.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656861      PMCID: PMC245178          DOI: 10.1128/AAC.35.7.1391

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Tissue distribution of 14-C-rifampicin I. Whole body autoradiography of albino mice.

Authors:  G Boman
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975-03

2.  Studies on the distribution and fate of S35-labelled benzylpenicillin in the body.

Authors:  S ULLBERG
Journal:  Acta Radiol Suppl       Date:  1954

3.  Partition data of penicillins determined by means of reversed-phase thin-layer chromatography.

Authors:  G L Biagi; A M Barbaro; M F Gamba; M C Guerra
Journal:  J Chromatogr       Date:  1969-05-20

4.  [Absorption, distribution, metabolism and excretion of rifampicin (3-(4-methyl-1-piperazinyl-iminomethyl) rifamycin SV) in the rat].

Authors:  T Akimoto; K Ono; T Nanpo
Journal:  Jpn J Antibiot       Date:  1970-06

5.  Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis.

Authors:  D Ungheri; C Della Bruna; A Sanfilippo
Journal:  G Ital Chemioter       Date:  1984 Sep-Dec

Review 6.  Rifampicin, a general review.

Authors:  G Binda; E Domenichini; A Gottardi; B Orlandi; E Ortelli; B Pacini; G Fowst
Journal:  Arzneimittelforschung       Date:  1971-12

7.  LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies.

Authors:  C Della Bruna; G Schioppacassi; D Ungheri; D Jabès; E Morvillo; A Sanfilippo
Journal:  J Antibiot (Tokyo)       Date:  1983-11       Impact factor: 2.649

8.  Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man.

Authors:  R Battaglia; E Pianezzola; G Salgarollo; G Zini; M Strolin Benedetti
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

  8 in total
  1 in total

Review 1.  A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.

Authors:  Russell R Kempker; Wael A Alghamdi; Mohammad H Al-Shaer; Gena Burch; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.